Impax Asset Management‘s “Impax US Sustainable Economy Fund” released its Q4 2025 investor letter. A copy of the letter can ...
Merck & Co. Inc. stock reached a 52-week high, closing at $122.69. This milestone highlights a significant upward trend for the pharmaceutical giant, marking a notable recovery and growth over the ...
Merck & Co. Inc. MRK on Wednesday announced a strategic collaboration with Mayo Clinic to leverage artificial intelligence ...
Merck & Co., Inc. (NYSE:MRK) is one of the best medical research stocks to buy according to hedge funds. Merck & Co., Inc.
Merck & Co. is no longer a deep-value patent cliff trade but a fairly valued defensive compounder. Read why I have downgraded ...
Merck shares began peeling back in early 2024, mostly on concerns about looming patent expirations for its breadwinning drug. The trading crowd changed its collective mind a couple months ago, sending ...
Merck (NYSE: MRK) stock rose 2% Friday morning after Deutsche Bank analyst James Shin upgraded the pharmaceutical giant from Hold to Buy, setting a price target of $150.00, up from $115.00.
We recently published Wall Street Analysts Like These 10 Stocks. Merck & Co., Inc. (NYSE:MRK) is one of the stocks analysts were recently talking about. Bill Nygren, Oakmark Funds partner and CIO, ...
New KEYTRUDA indications are expected to preserve Merck's top line. Click here to read why MRK stock remains a great buy upon correction.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results